NEW YORK – Akoya Biosciences said Tuesday that it has received CLIA certification for its Advanced Biopharma Solutions laboratory.
The Marlborough, Massachusetts-based firm said that the certification would allow it to support later-stage clinical trials with its biopharma partners and was a step toward advancing its spatial imaging platform for clinical use.
"Securing CLIA certification for ABS demonstrates our commitment to meeting the highest quality standards,” Akoya CEO Brian McKelligon said in a statement. "This is an important step in support of our effort to work with our biopharmaceutical partners to identify biomarkers that lead to better clinical decision making and improved patient outcomes."
On the company's Q3 2021 earnings call, McKelligon said Akoya has inked a number of agreements with biopharma firms for fee-for-service work on clinical trial samples using its Phenoptics single-cell imaging system, which is aimed at the translational and clinical markets.
It also has ongoing collaborations with pharma companies, including AstraZeneca, with which it signed a partnership in June for spatial biomarker analysis for immuno-oncology drug development.